3D Printing is Revolutionizing the Medical Devices World, but are Payers Ready?
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Recent progress in healthcare applications of 3D printing is changing modern medicine in unprecedented ways. As an example, 3D printed implantable medical devices have the potential for significant innovation and clinical advantages in addressing unmet needs, such as:
• Creating customized implants fit for purpose and tailored to meet a patient's individual anatomy, 1 which can result in faster recovery time and less complications 2
• Providing a more cost-effective alternative to current devices and implants 1 by being better adapted to individual patient needs • Allowing surgeons to visualize deformity, plan, and prepare for surgery, in addition to reducing time spent on fitting the device during surgery 1, 2 However, 3D printed devices and implants also present an array of uncertainties and potential risks, including:
• Quality control in manufacturing 3 and consequent challenges for licensing and safety control • 3D printed devices need to be produced fit for purpose and are likely to result in additional preparation time for patients and surgeons -conventional implants and devices are readily available 2 So, how do we capture the value of the disruptive innovation of 3D printed medical devices for reimbursement? To understand the situation better, this article highlights the following questions.
• How are regulators evaluating 3D printed medical devices, and what impact may this have on how these devices enter the market?
• How are 3D printed devices evaluated from a reimbursement and market access perspective, and what are the implications for access considerations on overall market acceptance?
• What are the challenges from a market access perspective for new 3D printed medical implantable products, and what can device manufacturers do to address them?
To guide our answers, desk research and interviews with payers, surgeons, and industry experts in the U.S. and several European markets (France, Germany, Belgium, Sweden, Spain, and Switzerland) were conducted in late 2014 and early 2015. 2
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Where do regulators stand?
Europe -Regulation of 3D printed devices is not in the EU regulatory framework yet because regulatory burden is perceived to be "low"
"Manufacturers of medical devices for an individual patient, so-called 'custom-made devices', must ensure that their devices are safe and perform as intended, but their regulatory burden remains low." -European Commission, 2012 4 Manufacturers, however, would like transparency and clarity around the regulation of 3D printed medical devices.
For example, Materialise, a provider of 3D printing software and services, points out that 3D printed medical devices are bundled under the same group as orthopaedic insoles. 5 "Regulatory rules for orthopaedic insoles should be different from rules for 3D-printed surgical guides, implants and plates, since the latter will require more stringent quality requirements. For this reason, the very broad 'custom-made medical devices' category does not seem to accurately address the needs and potential risks of using 3D printing to design, produce and use patientspecific medical devices." -Materialise, September 2014 5
U.S. -Regulation of 3D printed medical devices is on the U.S. radar (FDA)
Currently, U.S. regulation of 3D printed devices is not significantly different from the regulation of conventional medical devices. 6 "Not all devices or additive manufacturing technologies have the same risks or degrees of concern" -FDA, October 2014 The U.S. Food and Drug Administration (FDA) recommends that 3D manufacturers schedule a presubmission meeting to discuss the product with the FDA review team. 8 However, the rapid rise of 3D printing for medical applications raises a lot of questions. To address safety concerns, the FDA created a working group to assess technical considerations in 3D printing. 8 The first public workshop, titled "Additive Manufacturing of Medical Devices: An Interactive Discussion on the Technical Consideration of 3D Printing" was held October 8-9, 2014. 9 The goal of the workshop was for the FDA to better understand technical aspects of 3D printing technology, which will eventually contribute to how the regulatory landscape is established.
Manufacturers should push for a clear EU regulatory guidance on 3D printed implantable devices so that patient safety is continuously ensured.
Manufacturers should use opportunities, such as public workshops on 3D devices, to collaborate with the FDA on the development of future 3D printing regulatory framework and to ensure that patient safety is preserved.
ORTHOPEDIC INSOLES IMPLANTS
"Custom-Made Medical Devices" Category
EU Regulatory Framework
Big Variation in Medical Risk
If a patient requires a sophisticated surgery, fitting the device during the surgery may not be the most effective/easiest option due to possibility of poor fit, risk of complications, and more uncertainty in outcomes.
With 3D printing technology, the majority of time is spent pre-planning the surgery.
Are surgeons willing to drive uptake of 3D printed medical devices?
Where cost is less of an issue, "hassle factor," financial incentives, and P4P schemes may significantly affect the uptake of 3D printed medical devices for the mainstream patient 2
• The more complicated process may prevent mainstream use of 3D printed customized medical devices (hassle factor)
• For surgeons financially incentivized by operating on more patients, impact of 3D on operating theatre efficiency will be key • Pay-for-performance (P4P) metrics may be another strong driver for the surgeon and for the hospital (e.g., for prestige and profitability reasons)
Whether it is challenges in reimbursement, incentive schemes, or the hassle factor, surgeons emphasize that they are more likely to use 3D printing technology only in special cases. 2 • Can be a national, regional, or local payer (e.g., CFO, dept. head)
With Standard Devices With 3D Printed Devices
The majority of payers have not dealt (knowingly) with 3D printed devices.
There is "undiscovered need" for 3D printed devices amongst surgeon community.
Many payers mention they would not know if they are dealing with a 3D printed device (vs. device produced via regular manufacturing technique) because of the Diagnostics Related Groups (DRG) (i.e., bundled) method of payment.
"If it is a desperate situation, we could accept a very high price for a 3D printed custom-made device. But if you start with a very high price, that's something I would need to negotite carefully with my boss. If there is another option that seems reasonable with a much lesser price, I would go for that option." -Surgeon at a public hospital, Sweden
Having a solid understanding on the reimbursement route of 3D printed devices will be key for reimbursement, optimal value proposition, and preparing the substantiating evidence.
Potential DRG scenarios for a novel 3D printed medical device: another market access complication? 2
A Three potential scenarios for reimbursement of a new 3D printed medical device within the DRG system.
Level of price premium of 3D printed medical devices (vs. conventional devices)
No HTA assessment
Bundled under existing DRG code REASONS 1. No significant impact on budget 2. Assumption that 3D printed, custom-made device is better, hence better value for money vs. currently available options 3. Time constraints -payers have "other things to worry about" 3D printed medical devices with a higher price premium vs. conventional devices will face a higher degree of scrutiny. 2 "It is likely that we will see that AMNOG approach will be applied to the medical devices market soon. Due to the scandals we've seen in France and Germany with breast implants, politicians say that we need better quality control and implementation of added benefit rating. The question is 'When?' What that means for 3D printing companies is that they will need to submit a dossier to the G-BA in addition to getting a CE mark." -Advisor to head of Doctor's Association (KV), Germany 
HTA assessment
Prioritizing next steps across markets for developing a comprehensive action plan for 3D printed devices
Informing stake-holders Launch Strategy
Value Proposition
Evidence Generation
Price Exploration
Regulation Clarity 1 There are many opportunities for 3D printing of specific medical devices (anything that benefits from customization)
2 Success will depend on balance between consolidated workload (pre-and during surgery) and safety aspects (wear and tear)
3 The commercial problem is the current lack of regulations for in-hospital printed devices, which threatens the 3D industry and the patient (as quality control cannot be on same level as industrial made)
4 Payer interests will depend on pricing of 3D printed device vs. medical devices printed via conventional techniques • from no interest if within same DRG
• to high interest if with additional budget • or need for higher DRG 5 Key point to find out is cost effectiveness (or efficiency) of 3D printed medical devices versus standard devices, e.g., impact on direct medical cost and length of surgery
Lessons Learned
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